Metformin shows promise against mitochondrial damage in Wilson disease mice
A UC Davis study found improved mitochondrial measures in a mouse model, but whether the diabetes drug could help people with Wilson disease remains unknown.

UC Davis Health researchers found that metformin, a drug widely used to treat type 2 diabetes, improved signs of mitochondrial dysfunction in a mouse model of Wilson disease. The effect was especially noticeable in female mice. The findings point to a possible new research direction, not an established treatment for people with the rare genetic condition.
Wilson disease prevents the liver from effectively removing copper. As copper builds up, it can harm the liver, brain, eyes and kidneys, as well as mitochondria, which help cells produce energy. Current approaches include copper chelation, which removes copper from the body, and dietary restrictions. The UC Davis team is investigating whether targeting mitochondrial damage could address effects that copper-focused treatments do not.
The study was published in Nature Scientific Reports. Researchers examined metformin in an animal model; the source does not say that the drug has been tested as a Wilson disease treatment in people. Its potential benefit and safety for that use therefore remain unknown.
What changed in the mice?
The female mice had more severe mitochondrial injury than the males, but also responded more to metformin and had higher levels of the drug in their blood. After treatment, mitochondria in the females became larger, rounder and smoother, according to the study description. The researchers said human patients show a similar sex-related pattern in symptoms, with women often experiencing more severe symptoms, though the reasons are not yet known.
Metformin is of interest partly because it is already widely used and has been extensively studied for diabetes. The research team also noted that the drug can bind to metals, including copper. The study’s findings do not establish whether that property or its effects on mitochondria explain the changes in the mice.
What happens next?
Further research is needed to determine whether metformin, or other drugs that support mitochondrial function, could benefit people with Wilson disease. UC Davis researcher Valentina Medici said the team is exploring whether existing medicines could be repurposed for this purpose. No clinical treatment recommendation or timeline for human testing was announced.
Early detection may be important because Wilson disease symptoms can begin later in childhood or, in some cases, middle age. Medici said there is a push to include the condition in newborn screening. The source does not say whether it has been added to any screening program. Researchers hope early diagnosis and access to effective therapies could delay or prevent severe liver disease and neurological or psychiatric symptoms, but the mouse findings do not show that metformin can do so.
This report draws on information from welcome.
Editorial checks passed Facts, figures and quotes checked against 1 source, 1 official or primary
Add Clinic Near Me as a preferred source on Google



